PIP is a BioDefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. It has five product candidates in various stages of development. In general, we're going to be buying more Pharms this year. PIP may be this year's XOMA (without the desperate downtrailing before the payoff). Our bet is the Profit-Taking will come early because of a lawsuit which may be decided with and out-of-court settlement (view file) as early as this month. Still, would have faith in Long (hey, we did do an S/L).
View Case File
No comments:
Post a Comment